Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea-Reference-Cited by-同舟云学术

Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea

Published:2021-01-26 Issue:1 Volume:8 Page:395-409
ISSN:2198-6576
Container-title:Rheumatology and Therapy
language:en
Short-container-title:Rheumatol Ther

Author:

Ha So-Young,Shim Yoon-Bo,Lee Min-Young,Koo Bon-San,Kim Jae-Hoon,Jeon Ja-Young,Yoo Hyun-Jeong,Kim Young-Joo,Shin Ju-Young,Park Mi-Hai^ORCID

Funder

Pfizer Pharmaceuticals Korea Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s40744-021-00278-z.pdf

Reference35 articles.

1. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.

2. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–19.

3. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–61.

4. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65(3):559–70.

5. Muszbek N, Proudfoot C, Fournier M, et al. Economic evaluation of sarilumab in the treatment of adult patients with moderately-to-severely active rheumatoid arthritis who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. Adv Ther. 2019;36(6):1337–57.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2024-08-11

2. Cost of treating rheumatoid arthritis in the primary care public health system in Ireland: A time-driven activity-based cost analysis;Exploratory Research in Clinical and Social Pharmacy;2024-06

3. Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies;Frontiers in Pharmacology;2022-12-13